Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.89M | 330.96M | -282.85M | -179.95M | 196.89M |
| Total Depreciation and Amortization | 10.41M | 10.59M | 5.25M | 18.45M | 10.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.21M | 42.02M | 69.29M | 176.14M | 4.07M |
| Change in Net Operating Assets | 143.34M | -586.25M | 339.51M | -29.23M | 49.53M |
| Cash from Operations | 197.07M | -202.68M | 131.21M | -14.59M | 261.34M |
| Capital Expenditure | -555.00K | -2.08M | -3.59M | -22.93M | -31.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.82M | -132.31M | 99.80M | 255.33M | 64.01M |
| Cash from Investing | -93.37M | -134.39M | 96.21M | 232.40M | 32.21M |
| Total Debt Issued | 175.00M | 250.00M | -- | -- | -- |
| Total Debt Repaid | -175.00M | -250.00M | -35.13M | -123.94M | -304.00K |
| Issuance of Common Stock | 0.00 | 241.00K | 308.00K | 21.21M | 1.50M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | -25.01M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -4.38M | -15.06M | -- |
| Cash from Financing | 0.00 | 241.00K | -39.21M | -117.79M | -23.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.70M | -336.83M | 188.21M | 100.03M | 269.73M |